Compare Aterian Inc (ATER) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Quest Diagnostics Inc — how do they compare? Aterian Inc trades at $0.49 (market cap $5.32M), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 4926.7× Aterian Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | DGX | |
|---|---|---|
Market Cap | $5.32M | $26.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $238.50 |
52-Week Low | $0.36 | $173.49 |
Enterprise Value | $5.90M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ATER trades at $0.47, down 2.56% today, with a bearish technical signal despite recent earnings beats. The company shows deteriorating fundamentals with revenue declining from $221M in 2022 to $69M in 2025 and negative net margins. However, positive developments include a pending asset sale expected to return $0.85-$1.14 per share to stockholders, with proxy advisors recommending approval.
The stock faces significant fundamental challenges with persistent losses and negative cash flow, but the proposed asset sale provides potential near-term catalyst. Analyst sentiment is divided with 50% buy ratings. Key risks include execution of the asset sale and ongoing operational losses, while the technical picture remains bearish near-term.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
